408359-52-4

Basic information

• Product Name: Ethanone, 1-(3-cyclopropylphenyl)- (9CI)
• Synonyms: Ethanone, 1-(3-cyclopropylphenyl)- (9CI);1-(3-Cyclopropylphenyl)
• CAS NO: 408359-52-4
• Molecular Formula: C₁₁H₁₂O
• Molecular Weight: 160.21238
• Product Categories: ACETYLGROUP
• Mol File: 408359-52-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethanone, 1-(3-cyclopropylphenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(3-cyclopropylphenyl)- (9CI)(408359-52-4)
• EPA Substance Registry System: Ethanone, 1-(3-cyclopropylphenyl)- (9CI)(408359-52-4)

Safety Data

• Hazardous Substances Data: 408359-52-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(3-cyclopropylphenyl)(9CI) is used as a potential candidate for the development of new drugs due to its unique structure and properties. Its aromatic and cyclopropyl groups may contribute to the creation of novel therapeutic agents with specific pharmacological activities.
Used in Flavor and Fragrance Industry:
Ethanone, 1-(3-cyclopropylphenyl)(9CI) is used as a potential ingredient in the development of flavors and fragrances. Its distinct chemical structure may impart unique and desirable sensory properties to various consumer products, such as food, beverages, and cosmetics.
Used in Organic Synthesis:
Ethanone, 1-(3-cyclopropylphenyl)(9CI) serves as an intermediate in organic synthesis, enabling the production of more complex molecules and compounds. Its versatile structure allows for further chemical modifications and reactions, facilitating the synthesis of a wide range of organic compounds for various applications.

Upstream product

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 411235-57-9 cyclopropylboronic acid 
• 39172-32-2 2-(3-bromophenyl)-2-methyl-[1,3]dioxolane 
• 23719-80-4 cyclopropylmagnesium bromide 

Downstream Products

• 627463-23-4 2-bromo-1-(3-cyclopropylphenyl)ethan-1-one 

Relevant articles and documents

BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF

The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

Facile synthesis of aryl(het)cyclopropane catalyzed by palladacycle

Sphos (2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′- biphenyl) adduct of cyclopalladated ferrocenylimine (IIe) exhibited highly catalytic activity for the Suzuki cross-coupling reaction of cyclopropylboronic acid with aryl(het) halides with 1 mol % catalyst loading. This process was applied to both of aryl and heteroaryl halides (Br and Cl), and made the various arylcyclopropane and heteroarylcyclopropane to be easily synthesized. A variety of substituents on the aryl halides, such as alkyl, acetyl, benzoyl, ether, formyl, carboxylate, methoxy, nitro and cyano were tolerated.

DIAMINOTHIAZOLES

The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.